AMCP Submits Comments to FDA on BsUFA II Reauthorization, Citing a Need for Robust Biosimilars Education, Expeditious and Harmonious Guidance Documents, and Post-Market Surveillance
AMCP Submits Comments to FDA on BsUFA II Reauthorization, Citing a Need for Robust Biosimilars Education, Expeditious and Harmonious Guidance Documents, and Post-Market Surveillance